BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 21, 2019--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host a conference call on Thursday, February 28,
2019, at 5:00 p.m. ET to discuss its financial results for the quarter
and full-year ended December 31, 2018, and recent operational highlights.
To access the live call by phone, dial (877) 497-1438 (domestic) or
(262) 558-6296 (international) and enter the passcode 4097229. To access
a live or recorded webcast of the call, please visit the Investor
Relations section of the Aimmune Therapeutics website at www.aimmune.com.
The recorded webcast will be available for approximately 30 days
following the call.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing
oral treatments for life-threatening food allergies. The company’s
Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is
intended to provide meaningful levels of protection against allergic
reactions resulting from accidental exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4–17 years of age. Aimmune’s regulatory filing for marketing approval of
AR101 in the United States (submitted 4Q18) is based on data from the
pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old
subjects met its primary and key secondary endpoints, and additional
ongoing and completed AR101 clinical trials. Aimmune expects to file for
marketing approval of AR101 in Europe in the first half of 2019. Aimmune
has filed an IND application for its second product, AR201, for the
treatment of egg allergy and intends to start a randomized Phase 2
clinical trial in the first half of 2019. For more information, please
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005174/en/
Source: Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D., 650-396-3814
Alison Marquiss, 650-376-5583